GSK Lapatinib Breast Cancer Filing Delayed; Focus Shifts To Front-Line
This article was originally published in The Pink Sheet Daily
Executive Summary
Following favorable Phase II interim results, lapatinib clinical efforts will be refocused on the front-line setting, GSK says. Phase III program is ongoing. Firm had planned to submit based on Phase II studies in highly refractory disease, but results were not sufficient for filing.
You may also be interested in...
GSK Broadens Scope Of Clinical Studies For Breast Cancer Therapy Lapatinib
The company outlined an expanded Phase III development program for Tykerb (lapatinib) during an oncology R&D update.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.